What’s Left After Joe Manchin Pulls the Plug On Tax and Spending Package?
Author: Greg Valliere
July 15, 2022
PULLING THE PLUG: The executioner, not surprisingly, was Sen. Joe Manchin, the
centrist Democrat who proclaimed this week that spending and tax proposals will have to wait until inflation subsides.
THE BIG MARKET IMPLICATION: Even though Manchin supports killing some of the Trump tax cuts, he won’t move on this any time soon. His Senate ally, Democrat Kirsten Sinema, also opposes tax hikes, so the Democrats are two votes short — which means investors won’t have to worry about changes to capital gains rates, the estate tax, the step-up basis, higher top rates or the global minimum tax.
IN FACT, WE THINK the threat of any significant tax hikes has subsided for years to
come, based on our belief that the House will flip back to the Republicans in the
Nov. 8 elections. The GOP will gain control for 2023-24, meaning tax hikes may be dead until later this decade.
SO — WHAT’S LEFT? Stunned Democrats, furious at Manchin, still want to pass something before the election. He supports Medicare drug price negotiations and an extension of Obamacare subsidies, two issues that poll very well for the Democrats.
THE ISSUE WILL BE whether Democratic activists, who will fail to win environmental provisions and other spending, are willing to take far less than half a loaf. They already have abandoned more child care, free pre-kindergarten and tax benefits to low-income Americans — and have given up on greener energy, electric vehicles, curbing carbon emissions, etc.
ONCE THE SHOCK OF THE MANCHIN MOVE SINKS IN, Democrats probably will accept drug price negotiations. This would empower Medicare to negotiate for the price of certain high-cost drugs, limit beneficiaries’ out-of-pocket costs to $2,000 a year and extend premium and copayment assistance to some lower-income seniors. The lower drug costs potentially could fund an expansion of the Obamacare subsidies.
DRUG COMPANIES EMPLOY SOME OF THE BEST LOBBYISTS in Washington, and the industry will spend millions on TV ads that assert price controls will diminish pharmaceutical innovation.
THE INDUSTRY always wins this battle, but Democrats are willing to use the budget
reconciliation process to get drug price negotiations. At the least, the industry
faces headline risk for several weeks to come.
* * * * *
WE REITERATE YESTERDAY’S PREDICTION that Fed Chairman Jerome Powell is leaning toward a 75 basis point rate hike later this month, not a 100 basis point blockbuster. Powell has prepared the markets for 75, and undoubtedly must be worrying that chances of a recession would increase if he hikes rates by 100 basis points.
WITH OIL AND GASOLINE LEADING THE WAY, a case can be made that inflation data will look better in the next couple of months, so we’ll stick with our prediction of a 75 basis point hike from the FOMC and a hawkish Powell press conference on July 27.
The views expressed in this blog are provided as a general source of information based on information available as of the date of publication and should not be considered as personal investment advice or an offer or solicitation to buy and/or sell securities. Speculation or stated believes about future events, such as market or economic conditions, company or security performance, or other projections represent the beliefs of the author and do not necessarily represent the view of AGF, its subsidiaries or any of its affiliated companies, funds or investment strategies. Every effort has been made to ensure accuracy in these commentaries at the time of publication; however, accuracy cannot be guaranteed. Market conditions may change and AGF accepts no responsibility for individual investment decisions arising from the use of or reliance on the information contained herein. Any financial projections are based on the opinions of the author and should not be considered as a forecast. The forward looking statements and opinions may be affected by changing economic circumstances and are subject to a number of uncertainties that may cause actual results to differ materially from those contemplated in the forward looking statements. The information contained in this commentary is designed to provide you with general information related to the political and economic environment in the United States. It is not intended to be comprehensive investment advice applicable to the circumstances of the individual.
AGF Investments is a group of wholly owned subsidiaries of AGF Management Limited, a Canadian reporting issuer. The subsidiaries included in AGF Investments are AGF Investments Inc. (AGFI), AGF Investments America Inc. (AGFA), AGF Investments LLC (AGFUS) and AGF International Advisors Company Limited (AGFIA). AGFA and AGFUS are registered advisors in the U.S. AGFI is a registered as a portfolio manager across Canadian securities commissions. AGFIA is regulated by the Central Bank of Ireland and registered with the Australian Securities & Investments Commission. The subsidiaries that form AGF Investments manage a variety of mandates comprised of equity, fixed income and balanced assets.
About AGF Management Limited
Founded in 1957, AGF Management Limited (AGF) is an independent and globally diverse asset management firm. AGF brings a disciplined approach to delivering excellence in investment management through its fundamental, quantitative, alternative and high-net-worth businesses focused on providing an exceptional client experience. AGF’s suite of investment solutions extends globally to a wide range of clients, from financial advisors and individual investors to institutional investors including pension plans, corporate plans, sovereign wealth funds and endowments and foundations.
For further information, please visit AGF.com.
©2022 AGF Management Limited. All rights reserved.